10 results on '"Paris, Laura"'
Search Results
2. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
3. Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion
4. Associated Cancers in Waldenström Macroglobulinemia: Clues for Common Genetic Predisposition
5. Factors Predicting Transformation of Asymptomatic IgM Monoclonal Gammopathy
6. P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
7. OAB-011: Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial
8. Real-World Patterns of Utilization and Outcome of Market Approved Lenalidomide-Based Triplet Combinations in First Relapsed Multiple Myeloma Patients: Evidence from a Propensity Score Matched Analysis
9. Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability
10. Newly-Diagnosed, Non-Transplant Eligible Multiple Myeloma Patients: Determinants of Choice of First-Line Treatment in a Single-Center
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.